Diasorin S.p.A. +$0.00 +0% 00:00 Today
1D 1W 1M 3M 1Y 5Y Max
Jul 31 Expected
12.95% Profit Margin
Profitable 1.38B Revenue
178.11M Net Income
This list is based on the watchlists of people on Stock Events who follow DSRNY. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Roche Holding AG is a major player in diagnostics and pharmaceuticals, directly competing with Diasorin in the diagnostics and testing market. Abbott Laboratories
ABT
Mkt Cap 183.77B
Abbott Laboratories offers a wide range of diagnostics equipment and tests, including for infectious diseases, competing in the same space as Diasorin.
Danaher Corporation owns several companies in the diagnostics sector, including Cepheid and Beckman Coulter, making it a direct competitor. Thermo Fisher Scientific
TMO
Mkt Cap 257.71B
Thermo Fisher Scientific provides a broad array of diagnostics and research products, competing with Diasorin in the life sciences and diagnostics fields. Bio-Rad Laboratories
BIO
Mkt Cap 9.95B
Bio-Rad Laboratories, Inc. offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components, competing in diagnostics. Qiagen NV
QGEN
Mkt Cap 10.37B
Qiagen N.V. is known for sample and assay technologies for molecular diagnostics, applying competitive pressure in the diagnostics market. Becton Dickinson
BDX
Mkt Cap 53.9B
Becton, Dickinson and Company is a global medical technology company that offers diagnostic products and equipment, competing across several of Diasorin’s market segments.
Bruker Corporation offers scientific instruments and analytical and diagnostic solutions, competing in the advanced diagnostics field alongside Diasorin.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Show More
FAQs What is Diasorin S.p.A. stock ticker?▼ Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Diasorin S.p.A. stocks are traded under the ticker DSRNY.
When is the next Diasorin S.p.A. earnings date?▼ Diasorin S.p.A. is going to release the next earnings report on March 12, 2027.
What is Diasorin S.p.A. revenue for the last year?▼ Diasorin S.p.A. revenue for the last year amounts to 1.38B USD.
What is Diasorin S.p.A. net income for the last year?▼ DSRNY net income for the last year is 178.11M USD.
How many employees does Diasorin S.p.A. have?▼ As of November 8, 2026, the company has 3,260 employees.
In which sector is Diasorin S.p.A. located?▼ Diasorin S.p.A. operates in the Health & Wellness sector.
When did Diasorin S.p.A. complete a stock split?▼ Diasorin S.p.A. has not had any recent stock splits.
Where is Diasorin S.p.A. headquartered?▼ Diasorin S.p.A. is headquartered in Saluggia, Italy.